Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies.

Literature DB >> 3581099

Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies.

F J Mather, R M Simon, G M Clark, D D Von Hoff.

Abstract

A model describing the development of cardiotoxicity as a function of cumulative dose of a drug and other covariates is presented. Methods are given for testing and illustrating a cumulative dose effect. Also, equations for estimation of the probability of developing cardiotoxicity in the presence or absence of competing risks are given. The methods are illustrated for mitoxantrone by means of data obtained from Southwest Oncology Group studies.

Entities: Chemical Disease Species

Mesh：

Substances：
Mitoxantrone

Year: 1987 PMID： 3581099

Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960

Keyword Cloud
Cited

11 in total

Review 1. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.

Authors: L R Wiseman; C M Spencer
Journal: Drugs Aging Date: 1997-06 Impact factor: 3.923

2. Actin-binding compounds, previously discovered by FRET-based high-throughput screening, differentially affect skeletal and cardiac muscle.

Authors: Piyali Guhathakurta; Lien A Phung; Ewa Prochniewicz; Sarah Lichtenberger; Anna Wilson; David D Thomas
Journal: J Biol Chem Date: 2020-08-11 Impact factor: 5.157

3. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

Authors: E Kingwell; M Koch; B Leung; S Isserow; J Geddes; P Rieckmann; H Tremlett
Journal: Neurology Date: 2010-04-28 Impact factor: 9.910

Review 4. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors: V B Pai; M C Nahata
Journal: Drug Saf Date: 2000-04 Impact factor: 5.606

Review 5. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.

Authors: C J Dunn; K L Goa
Journal: Drugs Aging Date: 1996-08 Impact factor: 3.923

6. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis.

Authors: F X Weilbach; A Chan; K V Toyka; R Gold
Journal: Clin Exp Immunol Date: 2004-01 Impact factor: 4.330

Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies.

Review 1. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.

2. Actin-binding compounds, previously discovered by FRET-based high-throughput screening, differentially affect skeletal and cardiac muscle.

3. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

Review 4. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Review 5. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.

6. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis.

7. Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.

8. Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.

9. Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.

Review 10. Protective Effects of Chrysin Against Drugs and Toxic Agents.